BioGraphene Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

BioGraphene General Information

Description

Developer of novel graphene-based nanomedicine and drugs designed for neurodegenerative diseases. The company specializes in developing biomedical applications, medicines, and drugs through graphene synthesis using graphene-based materials for treating intractable and rare diseases like neurodegenerative diseases, and lysosomal storage diseases, enabling healthcare businesses to gain access to better tools to save and improve people's lives.

Contact Information

Website
www.bio-graphene.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • B-2nd Floor, Advanced Institute of Convergence Technology 145
  • Gwanggyo-ro, Yeongtong-gu
  • Suwon, Gyeonggi 16229
  • South Korea
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • B-2nd Floor, Advanced Institute of Convergence Technology 145
  • Gwanggyo-ro, Yeongtong-gu
  • Suwon, Gyeonggi 16229
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioGraphene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 21-Mar-2026 Completed Out of Business
1. Early Stage VC (Series A) 01-Apr-2019 Completed Pre-Clinical Trials
To view BioGraphene’s complete valuation and funding history, request access »

BioGraphene Patents

  • 53

    Total Documents Applications and Grants

  • Total Patents Families

  • 33

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

BioGraphene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023075259-A1 Gene delivery composition comprising nitrogen-doped graphene quantum dots Inactive 25-Oct-2021
JP-7621603-B2 Mri contrast agent containing carbon-13-containing graphene quantum dots and method for producing same Active 25-Aug-2020
JP-2023538734-A Mri contrast agent containing carbon-13-containing graphene quantum dots and method for producing the same Active 25-Aug-2020
EP-4197562-A1 Mri contrast medium including carbon-13-containing graphene quantum dot and preparation method therefor Pending 25-Aug-2020
EP-4197562-A4 Mri contrast medium including carbon-13-containing graphene quantum dot and preparation method therefor Pending 25-Aug-2020 A61K49/1818
To view BioGraphene’s complete patent history, request access »

Ready to get started?

Request a free trial

BioGraphene FAQs

  • When was BioGraphene founded?

    BioGraphene was founded in 2017.

  • Where is BioGraphene headquartered?

    BioGraphene is headquartered in Suwon, South Korea.

  • What industry is BioGraphene in?

    BioGraphene’s primary industry is Drug Discovery.

  • Is BioGraphene a private or public company?

    BioGraphene is a Private company.

  • What is BioGraphene’s current revenue?

    The current revenue for BioGraphene is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process